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Pairwise testing of Lentzea strains against Mycobacterium smegmatis to search for and 
identify new anti-tuberculosis compounds 




Tuberculosis remains one of the top ten causes of death worldwide. Therefore, immediate 
discovery of new antibiotic compounds is crucial for counteracting the evolving antibiotic 
resistance in strains of Mycobacterium tuberculosis and related species. Previous studies have 
shown that a soil bacterium, Lentzea kentuckyensis, can biosynthesize lassomycin, a peptide 
that has the ability to kill multi-drug resistant M. tuberculosis.  Two Lentzea strains were grown 
and observed to exhibit inhibitory activity against M. smegmatis. The active compounds were 
extracted and analyzed by mass spectrometry. Structure elucidation of the molecules by NMR 
spectroscopy is ongoing. Further studies will focus on determining the mechanism of action of 
the active compounds. Characterizing these metabolites will provide a better understanding of 
how Lentzea strains both interact with and defend themselves against competing microbes, such 
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Chapter 1: Introduction 
 
1.1 Tuberculosis (TB) Disease 
Tuberculosis disease (TB) remains one of the leading causes of death from a single 
infectious agent, Mycobacterium tuberculosis (Mtb), ranking above HIV/AIDS.1 In 2016, there 
were an estimated 1.3 million TB deaths among HIV-negative people and an additional 374,000 
deaths among HIV-positive individuals.1 
The treatment for drug susceptible tuberculosis disease is lengthy and runs for a total of 
six to nine months.2 This long and complex treatment regime leads to low or noncompliance of 
patients.1 As a result, low compliance of patients is one of the main factors that contributes to the 
re-emergence of the disease and the development of multidrug-resistant (MDR) tuberculosis, as 
well as the more severe form called extensively drug-resistant (XDR) tuberculosis.3 
Unfortunately, patients affected with extensively drug-resistant TB strain (XDR TB) are resistant 
to most TB drugs and are left with other treatment options that are much less effective.2 The 
emergence of drug-resistance of M. tuberculosis (Mtb) has been found to continually increase 
and is very difficult to treat.2 Antibiotic drugs used to treat tuberculosis were also reported to 
have adverse effects among HIV positive patients.2 Therefore, discovery of new antibiotic 
compounds is essential for counteracting the evolving antibiotic resistance of strains of 
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1.2 Epidemiology of Tuberculosis Disease 
In 2016, the World Health Organization (WHO) estimated that 10.4 million people 
were affected by TB disease, causing 1.3 million deaths among HIV-negative individuals 
and 374,000 more deaths among HIV-positive individuals.4 Similarly, in 2018, the WHO 
reported that 10 million people fell ill with TB disease.5 Among these affected patients, 1.5 
million people died with antimicrobial resistance being found to be the major cause of death.5 
Most cases were found to be in the regions of South-East Asia, Africa, and the Western Pacific 
(Figure 1.2.1).5 
Individuals living in warm countries with inadequate living conditions are more 
susceptible to TB and therefore reflect most of the global TB mortality. Patients that have 
completed the treatment for TB disease still tend to suffer from the damaging consequences of 
this disease despite of being cured from the infection, i.e. respiratory issues and reduced quality 
of life.4 Despite being one of the ‘old diseases’ known to mankind, the number of TB disease 
cases worldwide has remained stable until the 21st century. The WHO estimated that $2 billion 
US annually is required solely for TB research.5 
TB can be transmitted from one patient to another by the means of inhalation of droplets 
containing Mtb from an infected patient. Usually, the newly infected individual does not exhibit 
symptoms in the first few days. This condition is referred to as ‘asymptomatic’, and if the 
infection is kept under control, then the infected individual is diagnosed with latent TB but will 
not develop TB disease symptoms. Identification of Mtb strains in patients with latent TB is 
difficult and often remain undetected throughout the person’s life. In TB-patients, Mtb usually 
thrive in the lung alveoli but can also affect other areas of the body. Some of the important 
factors that increase the risk of contracting TB disease are malnutrition and protein 
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imbalance, which impairs the immune system and can lead to chronic renal failure requiring 
hemodialysis.4 Other risk factors for tuberculosis have also been found to include co-morbidity 
with diabetes mellitus (DM), smoking, and harmful use of alcohol.6,5 
 
Figure 1.2.1. Reported mortality incidence among HIV-negative (orange bars) and HIV-positive 
(blue bars) TB patients on top burden countries according to WHO Global TB Survey in 2018.5 
 
 
1.3 Tuberculosis Treatment 
Recent advances for early identification, diagnosis, and recommended approaches to treat 
significant subspecies of non-TB disease-causing mycobacteria (NTM) based from the literature 
and guidelines have become widely available. However, treatment success for NTM lung disease 
remains a challenge since available treatments are very lengthy and depends on the 
mycobacterial species.7 Combination of antibiotic drugs such as rifamycin, ethambutol and 
macrolides have been found to be effective against NTM.7 However, a common pathogenic 
mycobacteria species worldwide, Mycobacterium avium complex (MAC), was found to develop 
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Early diagnosis and immediate proper administration of cocktail combinations of anti-TB 
drugs decreases the duration of suffering from the common symptoms of TB disease in patients.4 
Treatment of TB normally  consists of several antibiotic drugs, usually taken as one of four 
regimens, each of which span six to nine months long (Table 1.3.1). Each regimen has an 
intensive phase of two months and a continuation phase of four to seven months.2 Currently, 
U.S. Food and Drug Administration (FDA) has approved ten antibiotic drugs to treat TB disease. 
The Centre for Disease Control and Prevention found that weekly administration of isoniazid 
(INH) and rifapentine (RPT) in combination under directly observed therapy (DOT) was very 
effective in active-TB disease prevention compared to other regimens. This new regimen appears 
to be completed more easily than the standard INH daily without DOT regimen for nine months. 
In the U.S., the CDC highly recommends this regimen to healthy patients ranging from twelve 
years and older that have LTBI and other factors that predict development of TB disease. 
Efficacy of this regimen is limited and is not recommended for patients aged two years and 
below, HIV-infected patients undergoing antiretroviral treatment, pregnant women, and patients 
who have LTBI that are known to have INH or RIF resistance.8  
Additionally, TB preventive treatment is widely encouraged by main health care 
intervention officials to reduce the risk of progression of latent TB infection to active TB disease. 
Children administered with the vaccine for bacilli Calmette-Guerin (BCG), are believed to be 
protected from the severe forms of TB disease.5 In 2018, fourteen vaccine candidates were in 
clinical trials. This includes prevention of development of latent TB infection and TB disease 
and improve success rate of TB disease treatment.5 There were also 23 drugs and several 
proposed combination treatment regimens in clinical trials for TB disease.5 Development of a 
universally effective vaccine for TB disease has been found to be difficult and slow throughout 
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the past twenty years. In 2018, two clinical trial results of TB vaccines showed promising 
results.9,10 However, many challenges need to be addressed before licensing and deployment of 
an effective TB vaccine for patients with latent Mtb infection.11  
Table 1.3.1. Drug Susceptible TB Disease Treatment Regimen. Intensive phase usually takes 
about two months, followed by the continuation phase that ranges from four to seven months. 
The treatment usually lasts for a total of six to nine months.2  
 
Intensive Phase Continuation Phase 
 
Regimen Drugs Interval and 
Dose 
Drugs Interval and 
Dose 
Range of Total 
Doses 
1 INH 7 days/week INH 7 days/week 182 - 130 
 RIF for 56 doses RIF for 126 doses 
 PZA or 5 days/week  or 5 days/week  
 EMB for 40 doses for 90 doses 
2 INH 7 days/week INH 3 times weekly 110 - 94 
 RIF for 56 doses RIF for 54 doses 
 PZA or 5 days/week    
 EMB for 40 doses   
3 INH 3 times weekly  INH 3 times weekly 78 
 RIF for 24 doses RIF for 54 doses 
 PZA     
 EMB     
4 INH 7 days/week INH twice weekly  62 
 RIF for 14 doses RIF 36 doses  
 PZA then twice weekly   
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1.4 Tuberculosis Drug Resistance 
Drug resistance has been reported to emerge as early as the first anti-TB drugs were first 
introduced.4 It was identified that past exposure to a cocktail of TB treatment is a strong 
predictor of TB drug resistance. In 2018, 7.0 million new cases of TB were reported globally, 
where 3.4% of new TB cases and 18% of previously treated cases were found to have multidrug-
resistant TB or rifampicin-resistant TB.5 This means that about half a million new cases of 
rifampicin-resistant TB have been reported and, of these, 78% had multidrug-resistant TB 
(MDR-TB). Additionally, cases of MDR-TB also include 6.2% with extensively drug-resistant 
TB (XDR-TB).5 This keeps the global treatment success rate of TB low.5 
Multidrug-resistant TB (MDR-TB) bacilli strains are resistant to any two of the most 
potent first-line anti-TB drugs, such as isoniazid and rifampicin. Extensively drug-resistant TB 
(XDR-TB) are MDR-TB strains that are also resistant to fluoroquinolones as well as to at least 
one of the second-line injectable drugs such as amikacin, capreomycin, and kanamycin. XDR-
TB has been reported to have caused outbreaks in some parts of the world.1  
Drug resistance arising from monotherapy was minimized by using combination 
therapy.4 Consistent intake of the prescribed antibiotic medications is essential to treat TB. 
Quitting the treatment regime early and taking the drugs incorrectly against instructions usually 
causes affected individuals to become sick again and emergence of drug resistant Mtb strains 
becomes more prevalent. M. tuberculosis strains that developed resistance to current antibiotic 
drugs available are more difficult and expensive to treat. Thus, completing the treatment for 
tuberculosis infection is very important to prevent development of active tuberculosis.  
Another key factor that Mtb has as a defense against antibiotics is its advantage of having 
a unique thick, waxy, hydrophobic cell envelope with drug degrading and modifying enzymes. 
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Another effective adaptation of Mtb and some pathogenic bacteria is the ability to horizontally 
transfer resistance determinants and chromosomal mutations from one bacterium to another. 
Chromosomal mutations help combat drugs by overexpressing or modifying the drug target thus 
altering the activity of the drug making it ineffective. Overall, these factors add up and enable M. 
TB to evolve drug resistance even when Mtb has a lower genetic diversity compared to other 
pathogenic bacteria. Understanding that there are numerous factors that affect drug resistance 
guides scientists to understand the appropriate target to inhibit the growth of M. TB.13 Similarly, 
pathogenic NTM species also evolve resistance to antibiotics such as macrolides. It was found 
that MAC strains are susceptible to macrolides in day three but develop resistance against 
macrolide antibiotic drugs after a prolonged incubation period of fourteen days.14 
Understanding mechanisms of antibiotic drug degradation and its possible causes in the 
environment is also critical to understanding the development of antimicrobial resistance. 
Degradation of some of the antibiotic class drugs used to inhibit the growth of pathogenic 
bacteria such as sulfonamides, trimethoprim, aminoglycosides, amphenicols and tetracyclines 
have been found to be problematic. Specifically, streptomycin, an aminoglycosides antibiotic 
class, which was isolated from actinomycetes such as Streptomyces sp. and Micromonosphora 
sp., was found to inhibit M. tuberculosis. The multicomponent nature of aminoglycosides and 
presence of impurities makes the assessment for the stability of amino glycosides difficult.15 
Semisynthetic approaches, microbial transformations, solid phase synthesis, resolution-
based strategies, and asymmetric synthesis have been used to synthesize anti-TB drugs.16 
Synthesis of some of these approved antibiotic drugs have been widely explored for a long time. 
Synthetic derivatives that target mycobacterial cell wall inhibitors include isoniazid, ethionamide 
prothionamide, ethambutol, cycloserine, pretomanid and delamanid.16 Additionally, compounds 
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that have been found to inhibit nucleic acid synthesis include, moxifloxacin, gatifloxacin, 




1.5 Natural Products Against Tuberculosis 
 
Natural products remain the most productive source of drug leads. It is a great starting 
point to make more potent synthetic derivatives to kill pathogenic bacteria. In fact, several TB 
drugs originated from natural products from various species of bacteria. Modification of the 
discovered natural products led to potential new drug candidates. For instance, Griselimycins, 
which is a cyclic peptide isolated from S. griseus and S. coelicus, was found to inhibit the growth 
of mycobacteria species including Mtb. However, further assays showed unfavorable 
pharmacokinetics properties, making it difficult to move on to clinical trials. Another compound 
included in the griselimycin family is cyclohexylgriselimycin. Cyclohexylgriselimycin was 
found to have enhanced antibiotic activity against Mtb. It is believed to target the DNA 
polymerase sliding clamp (DnaN), which ultimately prevents the bacterial growth and formation 
of gross lung lesions in patients with active TB.17 
Another natural product, cyclomarins A-C includes a small family of cycloheptapeptides. 
These were isolated from marine streptomycete CNB-982.18 One of the extracted metabolic 
compounds, cyclomarin A, was shown to inhibit the growth of Mtb and MDR-strains of Mtb by 
targeting ATPase ClpCl on mycobacteria species including M. bovis and M. smegmatis.19 
Another compound, Ecumicin was isolated from Nonomuraea sp. MJM5123. Eumicin was found 
to have antibiotic properties against mono-drug resistant, MDR, and XDR strains of M. TB and 
was found to be non-toxic to mammalian cells.20 Teixobactin, isolated from Eleftheria terrae, 
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was found to inhibit the growth of Staphylococcus aureus as well as Mtb H37Rv by binding to 
the peptidoglycan precursor lipid II and onto the cell wall teichoic acid precursor lipid 3.21 
Pyridomycin was isolated from Streptomyces albidofuscus, formally known as S. 
pyridomyceticus, and was found to be active against actively growing Mtb cultures. Pyridomycin 
was believed to target NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA, which is an 
essential enzyme for cell wall biosynthesis in Mtb. Pyridomycin also seems to retain activity 
against InhA-resistant strains.33 Additionally, new modes of action are associated with natural 
product-based inhibitors of Mtb.22 
One of these natural products that have shown to have activity against mycobacterium 
tuberculosis is lassomycin (Figure 1.5.1).23 Lassomycin is an antimicrobial peptide produced by 
the soil bacterium Lentzea kentuckyensis sp. and was discovered through screening of extracts 
from soil actinomycetes against M. tuberculosis. Lassomycin displays activity against MDR and 
XDR strains by targeting the binding site of ClpCl, leading to an increase in the ATPase activity 
of ClpCl and excessive protein degradation.24 
The discovery of the lassomycin peptide from soil bacterium L. kentuckyensis is the basis 
of this project. A phylogenetic tree for the members of the genus Lentzea and representative 
neighboring taxa, was calculated from 16S rRNA gene sequences using Kimura’s evolutionary 
distance method and the neighbour-joining method of Saitou & Nei. This shows that 
L. albida and L. albiodocapillata are closely related to L. kentuckyensis (Figure 1.5.2).25 
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Figure 1.5.1. Structure of lassomycin compound, a peptide produced by L. kentuckyensis that 
show activity against M. tuberculosis.24 
 
  
Figure 1.5.2. Phylogenetic tree for the members of the genus Lentzea and representative 
neighboring taxa. This was calculated from 16S rRNA gene sequences using Kimura’s 
evolutionary distance method and the neighbor-joining method of Saitou & Nei, 0.01 nucleotide 
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1.6 Liquid Chromatography and Mass Spectroscopy 
 
High-pressure liquid chromatography (HPLC) is a widely used type of elution 
chromatography. HPLC is used to separate and determine organic, inorganic, and biological 
compounds through gradient elution, where compounds are normally separated based on their 
polarity. Most sophisticated instruments used in academia and industry are commonly equipped 
with reverse-phase columns to improve separation of compounds. Using this technique, elution 
of analytes in increasing order of hydrophobicity is well-controlled by setting a known gradient 
or concentration of aqueous and organic solvent flowing into the column packed with 
hydrophobic resins. This method also incorporates a UV-Vis detector, a spectrophotometer 
instrument, which enables manipulation of wavelengths used to detect the presence of eluted 
compounds or analytes coming from the column. A UV-Vis chromatogram then shows a 
qualitative signal of the analyte corresponding to the selected wavelength as retention time 
increases. Calibration curve must be constructed to obtain quantitative data about the analyte. 
Covering the whole metabolome using a single analytical method is impossible because 
of the high diversity of molecular structures. Electrospray mass spectrometry (ESI‐MS) is also 
commonly used to analyze and identify the molecular masses of compounds.26 The output of a 
high-resolution mass spectrometer gives a fragmentation pattern for specific molecules. HPLC 
tandem with MS has a more powerful ability to identify the analyte. Mass spectroscopy (MS) 
will be used to determine the identity of the analytes corresponding to UV-Vis chromatograms. 
Compounds with different functional groups and molecular mass can be detected at the 
same wavelength. Detection of endogenous metabolites belonging to different chemical classes 
is possible using metabolite extraction procedures followed by direct use of ESI-MS analysis.27 
Incorporating chromatography reduces ion suppression, which is one of the main issues with MS 
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analysis of untargeted metabolites.28 Ion suppression is a type of matrix effect that can be defined 




The goal of this honours project is to investigate the potential activity of Lentzea bacteria 
species by focusing on two commercially available Lentzea strains called, L. albida and 
L. albiodocapillata. These Lentzea strains will be used to determine whether they produce 
bioactive natural products against M. smegmatis, a non-pathogenic mycobacterium strain that 
serves as a proxy for Mtb.25 Development of an efficient method to detect the presence of the 
bioactive compounds from a subject microbe against a target is critical part of this project. 
Compounds isolated in this study will be analyzed using the available instruments such as High-
pressure liquid chromatography equipped with reverse-phase C-18 column.  
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Chapter 2: Experimental  
Experimental work was done in a Containment Level 2 (CL2) laboratory according to the 
Canadian Biosafety Standards and Guidelines. The standard operating procedures for autoclave 
and biological safety cabinet usage were followed as indicated in the Saint Mary’s University 
Biosafety Manual, as well as in the Sit research group’s Standard Operating Procedures (SOPs). 
All active bacterial strain work was handled in a sterilized biological safety cabinet where all 
materials used were disposed in biohazard bins, which was collected and incinerated by an 
externally contracted service.  
2.1 Freeze–dried strains revival 
Freeze-dried strains of L. albida (ATCC 55006), L. albiodocapillata (ATCC 51859), and 
M. smegmatis (ATCC 27201) were ordered from the American Type Culture Collection 
(ATCC). These freeze-dried strains were carefully revived in the CL2 lab according to the 
Reviving Freeze-Dried Microorganisms Instruction Guide (see Supplementary information). For 
Lentzea strains, approximately 1.0 mL of the recommended media M65 broth was used to 
rehydrate and suspend the entire pellet. Most of the suspension was added to 4.0 mL of M65 
broth in a sterile tube. The last few drops of the suspension were transferred to an agar M65 slant 
as suggested by the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ). 
Inoculation of the revived Lentzea strains onto M65 agar media prepared in a regular-sized plate 
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2.2 Sample growth media 
Media  
M65: Gym Streptomyces Medium #65 consists of 4.0g glucose, 4.0g yeast extract, 10.0g malt 
extract, 2.0g CaCO3, 12.0g agar, and 1000 mL distilled water. The pH was adjusted to 7.2 by 
dissolving NaOH before the addition of agar and was then autoclaved for 30 minutes. For broth 
or liquid media, a similar procedure was followed without addition of CaCO3 and agar into the 
mixture. 
100% YMA: HiMedia consists of 3g yeast extract, 3g malt extract, 10g dextrose, 20g agar 
powder, and 1000mL distilled water. The pH was adjusted depending on the treatments, i.e. pH 5 
and pH 7, before addition of agar powder and autoclaving for 30 minutes. 
MB7H9: Middlebrook 7H9 Broth Base consists of 0.50 g/L ammonium sulfate, 2.50 g/L  
disodium phosphate, 1.00 g/L monopotassium sulfate, 0.0005 g/L calcium chloride, 0.001 g/L 
zinc sulfate, 0.001 g/L copper sulfate, 0.04 g/L ferric ammonium citrate, 0.50 g/L L-Glutamic 
acid, 0.001 g/L pyridoxine, 0.0005 g/L biotin. 
MB7H9 ADC Growth Supplement: Middlebrook ADC Growth Supplement consists of 0.05 
g/mL bovine albumin fraction V, 0.02 g/mL dextrose, 0.00003 g/mL catalase. 
Assay 
The growth of L. albida (L1) and L. albiodocapillata (L2) on M65 as well as in YMA 
media were examined. Both media were also treated with cycloheximide, a compound produced 
by Streptomyces griseus, which is routinely used for selection against yeast and fungi. This study 
was conducted to determine the ideal media for the Lentzea strains. Both Lentzea strains were 
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then grown in M65 liquid media and YMB liquid media at 28˚C with 150 rpm. Frozen stocks 
using (750 µL M65 liquid media and 750 µL 50% sterile glycerol) were also made for storage 
and future fresh bacterial culture use. Each Lentzea strain was grown in varying media 
conditions, such as in M65 media with and without cycloheximide, YMA media with and 
without cycloheximide, and pH 5.5 and pH 7.2.  
Revived M. smegmatis strains were grown in MB7H9 with ADC nutrient supplemented 
liquid media and inoculated in MB7H9 with OADC nutrient supplemented agar media and was 
incubated at 37˚C for a week. M. smegmatis was also inoculated on agar media with different 
concentrations of Yeast Malt extracts (10%, 50%, 100% YMA). This was done to determine if 
the amount of available nutrition in the medium causes the inhibition of M. smegmatis growth. 
The plates were incubated at 37°C for seven days. 
 
2.3 SEM imaging preparation 
L. albida and L. albiodocapillata were imaged using a MIRA3 TESCAN Scanning 
Electron Microscope to observe morphological characteristics of Lentzea strains. The procedure 
for sample preparation was modified from Xiong et al, 2017.29 The sample was fixed for 2 hours 
in a 2.5% glutaraldehyde solution (0.450 mL phosphate buffer solution with pH 7.2, 0.050 mL 
25% glutaraldehyde solution). The solution was removed, and the sample was dehydrated with 
30%, 50%, 70%, 90%, and 100% ethanol solutions for 20 minutes at each concentration. The 
ethanol was removed, and the sample was placed under argon before the final drying treatment, 
hexamethyldisilazane (HMDS) for 10 minutes. The HMDS was removed and the sample was 
allowed to dry in a desiccator for at least 48 hours 
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2.4.1 Pairwise testing on prepared agar media in a petri-dish 
Frozen stocks of Lentzea strains were inoculated on YMA media and were incubated at 
30°C to check for good growth and absence of contamination. After 7 days, each Lentzea strain 
was inoculated on prepared Yeast-Malt Broth liquid culture and was then incubated at 30°C for 2 
days. Similarly, a frozen stock of M. smegmatis was used to inoculate MB7H9 + OADC + agar 
media and was incubated at 37°C. After 7 days, M. smegmatis colonies from the agar plate were 
used to inoculate MB7H9 + ADC liquid media, which was incubated for another 2 days at 37°C 
with 150 rpm. 
Pairwise test A.1: Each Lentzea strain was then inoculated on one side of a prepared YMA agar 
in a 100 mm diameter sterile petri dish (Fisherbrand). M. smegmatis from liquid culture was then 





Figure 2.4.1.1 Pairwise bioassay diagram between a Lentzea strain and M. smegmatis on an agar 
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Pairwise test A.2.1: Each Lentzea strain was then inoculated on one side of a prepared YMA 
media in a 12-well-plate (Fisherbrand; diameter of well 22mm). M. smegmatis was then 
inoculated on the other side of each dish. These plates were then incubated at 37°C and were 
observed for one week. 
Pairwise test A.2.2: Similarly, each Lentzea strain was then inoculated on one side of a prepared 
YMA media in 12-well-plate (Fisherbrand; diameter of well 22mm). The pre-treated plates were 
incubated for two weeks at 30°C. Then, M. smegmatis was inoculated on the other side of each 
pre-treated well. These plates were incubated at 37°C and were observed for one week. 
Pairwise test B.1: No-contact pairwise bioassay 
The middle section of the YMA media poured on 60 mm diameter petri dishs (Fisherbrand) was 
removed using a sterilized scalpel. Each Lentzea strain was inoculated on each prepared plate, 
which was then incubated at 37°C for two weeks. M. smegmatis or B. megatarium were then 
inoculated on the other side of the media and were incubated for one week at 37°C. 
 
Figure 2.4.1.2 No-contact pairwise bioassay between Lentzea strain against M. smegmatis. 
Middle section of the prepared YMA media was removed. Each Lentzea strain was inoculated on 
one side of the sectioned media while M. smegmatis was inoculated on the other. Pairwise Test 
B.1 follows this test set-up. 
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2.4.2 Bioassay using 0.03 µm pore-size membrane 
YMA media with pH 7.2 was poured onto a 100mm diameter petri-dish and was left to 
solidify. Autoclaved 0.03 µm pore size membrane was carefully placed on the top of the agar 
media, and then approximately 5 mL of YMA media was poured on top of the membrane. Each 
Lentzea strain was inoculated on the top YMA media layer and incubated at 30°C for 
approximately two weeks. After two weeks, the top YMA media layer with 2-week-old-Lentzea 
strains and 0.03 µm membrane was removed. M. smegmatis was then inoculated on the 
remaining YMA media layer and incubated at 30°C for a week. 
 
2.5 Large scale agar media Lentzea culture 
Each Lentzea strain was inoculated on YMA media with pH 7.2. Different sizes of petri dish 
were used to determine which size would encourage a high production of secondary metabolites. 
Different sizes used were as follows; regular sized petri dish (Fisherbrand; diameter 100mm); 
12-well plate (Fisherbrand; diameter 22mm); 24 well plate (Fisherbrand; diameter 15mm); large 
petri dish (Fisherbrand; diameter 150mm). Plates were incubated at 30°C for more than two 
weeks before extraction. For consistency and higher extract yield, Lentzea were grown in 12-
well agar media.  
 
2.6 Enzyme analysis API ZYM 
The soluble enzyme activity in L. albida and L. albiodocapillata cultures was determined 
by API ZYM. The API ZYM test kit is a semi-quantitative analysis of production of hydrolytic 
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enzymes and is widely used for identification of Gram-negative and Gram-positive bacteria and 
yeast. Each strip is composed of 20 microcupules containing dehydrated chromogenic substrates 
for 19 enzymatic reactions and a control. 65 μl of the Lentzea strain culture incubated for two 
weeks at 30°C were dispensed into the 20 microcupules. The API ZYM strips were covered and 
incubated at 30°C for 5 hours. Then, a drop of the commercial reagents ZYM A and ZYM B 
(bioMérieux) were added to all the microcupules to develop chromogenic substrates. The colour 
reactions were read after 5 minutes, and a numerical value ranging from 0 to 5 was assigned 
according to the colour chart provided by the manufacturer.  
 
2.7 Extraction from media and Solubility test of extract  
Lentzea strains grown in YMA media poured to the following plate sizes (i) regular sized 
(100 mm diameter) plates; (ii) small sized plates (60 mm diameter); (iii)12-well plates (60 mm 
diameter); and (iv) large surface area (150 mm diameter) plate. After three weeks of growth, 
solid agar inoculated with matured Lentzea cultures were extracted using the following solvents: 
(a) ethyl acetate; (b) 1:1 of chloroform/methanol and (c) acetone. The mass of concentrate for 
control agar media extract, L1 agar media extract and L2 agar media extract were then recorded. 
Evaporated ethyl acetate extracts, chloroform:methanol extracts, and acetone extracts were 
dissolved in methanol for further analysis. Additionally, solubility tests were conducted for 
acetone extracts using acetone, acetonitrile, ethanol, and methanol. Acetone extracts were then 
dissolved using methanol for further analysis such as LC/MS and HPLC/HR(QTOF)MS. 
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2.8 Well-Diffusion Method 
The procedure reported by Balouiri et al. was modified for our Well-diffusion Assay.30 
M. smegmatis was inoculated on the prepared YMA and MB7H9 + OADC + agar media. A 
sterilized glass-pipette was then used to poke wells on the prepared media. Concentrated crude 
extract solution samples (~15uL) were pipetted into each well and were then incubated at 37°C. 
After 3-7days of growth, the growth of M. smegmatis surrounding the treated wells was observed 
for presence of activity. Potential inhibition zone(s) were noted.  
    
Figure 2.8.1 Well-diffusion set up for testing activity of extracts against M. smegmatis. Left dish 
shows a diagram of wells with extract concentrate. Right dish shows an image of a well diffusion 
assay with two wells inhibiting the growth of the surrounding bacteria. 
 
 
2.9 Chromatography Analysis 
2.9.1 Thin Layer Chromatography (TLC) Analysis 
Approximately 10 mL of developing solvent were placed into a 150 mL beaker. A line 
about 1 cm from the bottom and another light pencil line 2 cm from the opposite side of the plate 
were drawn on the silica plate. Extract samples were loaded using microcapillary tubes onto the 
TLC plate by allowing the tip of the drop at the end of the capillary to touch the plate. After all 
spots were applied and allowed to dry, the TLC plate was placed onto the beaker with the 
developing solvent. The TLC plates were removed and allowed to dry after the solvent reached 
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the top line on the plate. The plate was observed and photographed under UV light at 254 and 
365 nm. The retention factor (Rf), which is commonly used to describe chromatographic 
behavior of sample solutes, was calculated by taking the center of each spot for the 
measurements of Rf which is equal to the distance travelled by each spot, divided by the distance 
travelled by the solvent front (Equation 1).31 
Retention factor value, Rf 
𝑅𝑓 =  
𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑡𝑟𝑎𝑣𝑒𝑙𝑒𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑠𝑜𝑙𝑢𝑡𝑒
𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑡𝑟𝑎𝑣𝑒𝑙𝑒𝑑 𝑏𝑦 𝑠𝑜𝑙𝑣𝑒𝑛𝑡
       Equation 1 
  
Figure 2.9.1. Thin Layer Chromatography set up on Acetone-extract samples of Control Agar, 
L1, and L2. 
 
2.9.2 Reverse-phase Column Chromatography Method 
Approximately 5 grams of C-18 resin was activated with 100% ACN. A clean plug of 
glass wool was inserted into the bottom of a clean glass-pipet. A few grains of fine sand were 
placed into the pipet, then the activated C-18 ACN slush was poured into the pipet until the level 
reached approximately an inch from the top. The column was then repeatedly rinsed with 20% 
ACN. 200 µL of concentrated extract samples were then loaded onto the prepared column. 
Elution was conducted using 2 pipet volumes of the following gradient: 20%, 40%, 60%, 80%, 
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and 100% ACN in ultrapure water. Fractions were then collected for further testing. The 
collected extract fractions were used for testing against M. smegmatis using well-diffusion 
method.  
2.9.3 Liquid Chromatography/Mass Spectroscopy Analysis 
Crude extracts were dissolved with HPLC grade MeOH solvent fractionated using a 
microcolumn packed with activated C-18 resin and varying acetonitrile gradient. Each collected 
fraction was then tested against M. smegmatis. Fractions that inhibit the growth of M. smegmatis 
were analyzed using an Agilent 1100 series liquid chromatography tandem with mass 
spectrometry (LC/MS), equipped with reverse phase C18 column, diode array detector (DAD) 
and ion trap mass spectrometer. The solvent system used in the LC run consists of 0.1% formic 
acid in water as Solvent A and 0.1% formic acid in acetonitrile as Solvent B. A drop of 88% 
formic acid was added to the LC samples prior to injection.   
For the ethyl acetate extracts, the elution of fractions using LC/MS started with 20% 
acetonitrile (with 0.1% formic acid) in water for 24 minutes, then 80% acetonitrile (with 0.1% 
formic acid) in water for another 3 minutes. Finally, 100% acetonitrile (with 0.1% formic acid) 
in water was eluted for another 3 minutes. The needle was washed with methanol between every 
injection and a 10-minute post-run was completed to flush the column. Compounds were 
detected using wavelengths of 212nm, 254nm, and 350nm. The mass spectrometer was operated 
in the positive mode with a temperature of 37°C. Samples were analyzed from 100m/z to 
2200m/z using electrospray ionization mass spectrometry.  
Another LC/MS run with a broader ACN gradient was conducted for ethyl acetate 
extracts. This time, the elution started at 10% acetonitrile (with 0.1% formic acid) in water for 10 
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minutes then to 30% acetonitrile (with 0.1% formic acid) in water for another 15 minutes. 
Gradient was then changed to 50% ACN for 5 minutes; then to 80% ACN for another 5 minutes. 
Finally, 100% acetonitrile (with 0.1% formic acid) in water was eluted for another 5 minutes. 
The needle was also washed with methanol between every injection and a 10-minute post-run 
was used to flush the column. 
For acetone extracts, an LC run was conducted using 10% acetonitrile (with 0.1% formic 
acid) in water for 3 minutes followed by 30% acetonitrile (with 0.1% formic acid) in water for 2 
minutes then 50% acetonitrile (with 0.1% formic acid) in water for 5 minutes, then 60% 
acetonitrile (with 0.1% formic acid) in water for 5 minutes, then 70% acetonitrile (with 0.1% 
formic acid) in water for 5 minutes, then 80% acetonitrile (with 0.1% formic acid) in water for 5 
minutes, then 90% acetonitrile (with 0.1% formic acid) in water for 5 minutes, and finally 100% 
acetonitrile (with 0.1% formic acid) in water for 5 minutes. Wavelengths of 212nm, 225nm, 
254nm, 275nm and 350nm were used for detection of compounds.  
Additionally, another LC run was performed for the same acetone extract samples using 
the same mobile phase gradient and LC parameters, with changes of wavelengths used for 
detection of compounds (195nm, 203nm, 205nm, 212nm, and 274nm). 
2.9.4 UV-Vis Analysis 
 
The UV/Vis spectra were recorded using a Cary 60 UV-visible spectrophotometer 
(Agilent, Santa Clara, CA). For all absorbance measurements, a 1 cm Quartz cuvette was used. 
The spectra were recorded in triplicate from 800 to 200 nm. The procedure was repeated for the 
chosen agar control and active L1 and L2 acetone extract fractions. The data was automatically 
reduced to csv files (see Appendix). 
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2.9.5 QTOF analysis 
Concentrated acetone-extracts such as YMA, L1, and L2 were dissolved in MeOH to 
have a final concentration of 5 mg/mL. 1.5 mL of each sample were then placed in clear glass 2 
mL vials with 12 x 32 mm diameter. A 1.5mL MeOH in a 2 mL glass vials was also prepared for 
the HPLC/HRMS run. Column used for reverse-phase liquid chromatography was the Poroshel 
120 EC-C18 Column (PN: 693975-302T; SN: USC FW 09973). The flow of elution was 0.600 
mL/min and the maximum pressure was 600 bar. The aqueous mobile phase was milli-Q water 
with 0.1% formic acid and the organic phase was acetonitrile with 0.1% formic acid. The 
gradient of elution started at 10% ACN then at 3 minutes changed to 30% ACN; then at 5 
minutes to 50% ACN; then at 10 minutes to 60% ACN; then at 15 minutes to 70% ACN; then 20 
minutes to 80% ACN; then at 25 minutes to 90% ACN; then at 30 minutes to 100% ACN; then 
at 35 minutes to 100% ACN. The ion source of QTOF mass spectroscopy was set to Dual ESI in 
positive mode. Drying gas flow was 3.0 L/min, the gas temperature was 300°C, and the nebulizer 
pressure was 15 psi.  
2.10 Fourier-transform infrared spectroscopy (FTIR)  
FTIR spectra of active Lentzea-ACN gradient eluted fractions were obtained to see 
potential functional groups present in the sample. FTIR spectra were recorded on the Thermo 
Scientific Nicolet 6700 FTIR spectrometer, using the attenuated total reflectance (ATR) 
technique from the Smart accessory with diamond crystal. Spectral data were collected in the 
mid-IR range (4000–600 cm−1) with 64 scans and 2 cm−1 resolution. A background spectrum (32 
scans) was recorded before every sample spectrum.32 See Appendix attached. 
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Chapter 3: Results and Discussion 
3.1 Freeze–dried strains revival 
Freeze-dried strains of L. albida (ATCC 55006), L. albiodocapillata (ATCC 51859), and 
M. smegmatis (ATCC 27201) ordered from ATCC were successfully revived. Growth of Lentzea 
and M. smegmatis strains were observed after two weeks. Normally growth of Lentzea colonies 
and formation of M. smegmatis colonies and biofilm can be observed as early as 3 days. It was 
noted that reviving frozen strains takes longer compared to re-streaking colonies from one agar 
media to another.  
    
Figure 3.1.1. Growth of Lentzea albida on different media. M65 Agar slant, M65 broth liquid 
culture, M65 agar media. 
 
  
Figure 3.1.2 Growth of L. albida and L. albiodocapillata on M65 media. Lentzea strains were 
inoculated and incubated under 37°C for 7 days. 
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Figure 3.1.3 Growth of M. smegmatis on MB7H9 with OADC supplement agar medium and 
YMA medium. Plates were incubated under 37°C for 7 days. 
 
3.2 Sample Growth Media Assay 
ATCC recommends using YMA media, while DSMZ recommends M65 media. The 
ingredients of these two media are similar with minimal difference in pigmentation. The two 
recommended media for incubation, M65 and YMA, were compared to determine the medium 
conditions most ideal for these strains.  
The rate of growth and appearance of the bacterial colonies are very similar compared to 
one other when each of the Lentzea strains were inoculated on M65 media and YMA media. 
Therefore, Lentzea strains were grown on YMA media for consistency and easier preparation 
compared to M65 media. The growth of M. smegmatis on YMA and MB7H9 supplemented with 
ADC media were also compared. Supplemented MB7H9 media is the recommended media from 
ATCC. The growth of M. smegmatis in both examined media were relatively similar with a 
difference of coloration, i.e. M. smegmatis colonies appears to have a tint of yellow compared to 
when it was inoculated on supplemented MB7H9, on which it appears to be opaque white. Since 
the overall growth is similar, it was concluded that using both media should be appropriate in 
comparing the presence or growth of M. smegmatis.  
The effect of addition of cycloheximide, as well as changes to the pH of the YMA media, 
were examined to determine if these conditions will serve as a signal to induce stress and affect 
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the growth of Lentzea strains. The ideal pH for Lentzea strains recommended by ATCC was pH 
7.2, whereas M. smegmatis ideally grows in slightly more acidic media, therefore growth of 
strains was also tested on YMA media adjusted to pH 5.5. On the other hand, cycloheximide 
is an antifungal produced by Streptomyces griseus. Treatment of cycloheximide on media is 
commonly used in microbiological research for the purpose of bacterial growth isolation by 
inhibiting fungal growth.33 All three strains were inoculated on YMA media with these 
treatments. Both Lentzea strains grew well under these conditions with no visible significant 
differences (Figure 3.2.1-2). Therefore, it was decided to inoculate the Lentzea strains in YMA 
media with pH of 7.2 for consistency.   
Growth of M. smegmatis on different media such as YMA was also examined and 
compared against the recommended medium, MB7H9 with OADC supplement agar medium. M. 
smegmatis was also inoculated on agar media with different concentrations of Yeast Malt extract 
(10%, 50%, 100% YMA). After a week of incubation at 37°C, the plates were observed and the 
growth of M. smegmatis on each plate was compared to one another. It was noted that M. 
smegmatis grew on all plates with only slight colony color differences (Figure 3.2.3). These 
findings suggest that M. smegmatis is able to thrive on different media conditions even when the 
nutrients available on the media are very limited. Therefore, the amount of available nutrition in 
the medium cannot account for the observed inhibition of M. smegmatis when inoculated on the 
same media with 2-week old Lentzea strains. This suggests that inhibition of growth observed is 
more likely caused by another factor such as the interaction of M. smegmatis with the potential 
active secondary metabolites produced by the Lentzea strains. 
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Figure 3.2.1. Growth of Lentzea albida on YMA, YMA with cycloheximide, M65, M65 with 
cycloheximide. L1 was inoculated and incubated for two weeks under 30°C. 
 
 
    
Figure 3.2.2. Growth of Lentzea albiodocapillata on YMA, YMA with cycloheximide, M65, 





Figure 3.2.3. M. smegmatis growth on two media, supplemented MB7H9 and different 
concentration of YMB. (from left to right) supplemented MB7H9, top view 100% YMA, bottom 
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3.3 SEM imaging  
 
SEM images of bacterial L1 and L2 colonies were recorded. It was founded that plating the 
samples with gold yields images with best resolution (Figure 3.3.1). 
 
 
Figure 3.3.1. SEM images of Lentzea strains, Lentzea albida and Lentzea albiodocapillata, used 
for pairwise bioassay against Mycobacterium smegmatis. 
 
 
Figure 3.4. Methodology Overview for Pairwise bioassay and Extraction of active compound 
against M. smegmatis.  
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3.4 Pairwise Bioassay 
 
3.4.1 Pairwise testing on prepared agar media in petri-dish  
Commercially available Lentzea strains, such as Lentzea albida (ATCC 55006) and 
Lentzea albiodocapillata (ATCC 51859) were grown against M. smegmatis (ATCC 27201). The 
growth of the two commercially available Lentzea strains, L1 and L2, were observed in year 
2017. 
Lentzea strains and M. smegmatis were inoculated side by side. The goal of conducting a 
pairwise bioassay between these two strains was to see if the Lentzea strains can produce 
compounds to slow or inhibit the growth of M. smegmatis.  
Pairwise test A.1:  
Each Lentzea strain was inoculated on one side of a prepared YMA media in regular-
sized with a diameter of 100mm petri-dish. M. smegmatis was then inoculated on the other side 
of the dish. After being incubated at 37°C for a week, both Lentzea strains and M. smegmatis 
were observed to grow well on these plates. The distance between Lentzea strains and M. 
smegmatis was significant, such that any possible secondary metabolites coming from both 
microbes could not reach and interact with one another. This explains why no inhibition, or no 
any interesting activity was observed. 
Pairwise test A.2.1-2: 
It is assumed that both bacteria would be able to interact with one another when they are 
not as far apart from each other as the first attempt at pairwise testing. After at least one week of 
incubation, both Lentzea strains and M. smegmatis were observed to grow well together. 
Interestingly, inhibition of M. smegmatis growth was observed when Lentzea strains 
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were inoculated initially on the plates and were given two weeks to grow on the media before M. 
smegmatis was introduced (Figure 3.4.1-4). This supports the idea that letting the Lentzea strains 
grow for two weeks on the YMA media enables the Lentzea strains to establish maturity and 
produce active secondary metabolites. Releasing secondary metabolites into the surrounding 
environment is their unique way to establish territory and inhibit other microbes from growing 
close to them. One of the unidentified secondary metabolites produced by both Lentzea strains 
stops M. smegmatis from invading their space and prevents competition for food in this nutrient-
limited area.  
Pairwise test B.1: No-contact pairwise bioassay 
Interestingly, the growth of the Lentzea and M. smegmatis were observed on each treated 
plate. Plates were composed of Lentzea strain inoculated on one side of the prepared plate for 
two weeks before M. smegmatis was inoculated on the other side of the media, of which the 
middle section of the YMA media was removed (Figure 3.4.1.5). 
This treatment was done to determine whether the secondary metabolites produced by 
Lentzea strains are volatile organic compound(s) (VOC) that affect and suppress the growth of 
M. smegmatis with no direct physical contact. It was concluded that the active secondary 
metabolite(s) was not volatile since the growth of M. smegmatis was unaffected. Therefore, 
isolation of the active compound was focused on its extraction from Lentzea-cultured agar media 
using solvent extraction and analyzing those compounds using chromatographic methods such as 
LC, LC/MS, HRMS(QTOF).  
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Figure 3.4.1.1. Pairwise bioassay between Lenzea strains, Lentzea albida (L1) and Lentzea 
albiodocapillata (L2), against M. smegmatis (M) when inoculated at the same time. All strains 
were inoculated 12-well-plates (22mm diameter) from liquid cultures. Prepared plates were then 
incubated at 30°C for two weeks. Note growth of Lentzea strains and M. smegmatis. 
 
 
Figure 3.4.1.2. Pairwise bioassay between Lenzea strains, Lentzea albida (L1) and Lentzea 
albiodocapillata (L2), against M. smegmatis (M). Each Lentzea strain from liquid culture was 
inoculated on each well (22m diameter). After two weeks, M. smegmatis from liquid culture was 
inoculated on the other side of each plate. Prepared plates were then incubated at 30°C for two 
weeks. 
 
   
Figure 3.4.1.3. PWA of L1 against M. smegmatis. M. smegmatis was inoculated on the YMA 
media after L1 was initially grown on the media for two weeks at 30°C  
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Figure 3.4.1.4. PWA of L2 against M. smegmatis. M. smegmatis was inoculated on the YMA 
media after L2 was initially grown on the media for two weeks at 30°C.  
  
    




3.4.2 Bioassay using 0.03 µm pore-size membrane 
 
To check whether the observed inhibition is due to the secondary metabolites produced 
by the Lentzea strains another pairwise bioassay was conducted. This method incorporates a 
membrane in-between the media, as well as pre-treatment of the top layer of the media (refer to 
section 2.4.2 for the full procedure). Inhibition of M. smegmatis was only observed when M. 
smegmatis was inoculated onto the secondary agar media containing the diffused metabolites 
produced by 2-week old Lentzea colonies (Figure 3.4.2.1). Interestingly, revival of M. smegmatis 
colonies that have merely survived the previous treatment was not successful. The few colonies 
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media. This suggests that the active compounds have lasting effects on the growth inhibition of 
M. smegmatis.  
 
 
Figure 3.4.2.1. Pairwise bioassay using a 0.03µm pore-sized membrane.  
 
 
3.5. Large scale Lentzea culture on agar media  
Each Lentzea strain was inoculated on four regular sized (100mm diameter) petri dishes; 
12-well (22mm diameter) petri dish; 24 well (15mm diameter) petri dish and large-sized (150mm 
diameter) petri dish. Some of the YMA media plates inoculated with L1 have a darker 
color than its normal color; therefore, these plates were initially separated. It was also observed 
that the plates with L2 have a darker color than that of L1. Lentzea cultures grown in 24-well 
agar media was more pigmented compared to Lentzea cultures grown in regular sized with 
100mm diameter petri dish and 12-well petri dish YMA media. The growth of Lentzea strains on 
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24-well (15mm diameter) agar media also took less time (7 days) for the Lentzea cultures to 
saturate the surface of the media. On the other hand, Lentzea cultures grown in large plates took 
longer and yielded a smaller amount of extracts. These were incubated at 30°C for more than 
three weeks before extraction. Therefore, Lentzea strain cultures were grown in 12-well (22mm 
diameter) agar media for consistency and higher extract yield.  
    
Figure 3.5.1. Growth of Lentzea strains on small-sized (60mm diameter) petri-dish YMA media. 
  
Figure 3.5.2. Lentzea strains inoculated on YMA media with pH 7.2 prepared on regular 
(100mm diameter) petri dish. L1 (left) and L2 (right) were inoculated and incubated for two 
weeks.  
   
Figure 3.5.3. Growth of Lentzea strains on YMA media with pH ~7.2 in large-sized (150mm 
diameter) plates. Normal L. albida, dark-yellow coloured L. albida, and L. albiodocapillata. 
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Figure 3.5.4. Growth of Lentzea strains on 24-well (15mm) YMA media. Note the yellowish 
pigment of L1 while the grayish pigment of L2 on yeast malt agar. 
 
  
Figure 3.5.5. Growth of Lentzea strains on 12-well (22mm) YMA media. Note lighter color of 
L1 and L2 on 12-well plates than of L1 and L2 on 24-well YMA plates.  
 
 
3.6 Enzyme Assay (API-ZYM) 
 
The readings of colour intensity of the enzyme reactions in each microcupule were 
recorded (Table 3.6.1). The enzyme assay indicates that alkaline phosphatase (AP) is present in 
L1. AP is known as a glycoprotein bounded on cell membranes that act as a catalyst of phosphate 
monoester hydrolysis reactions at basic pH values. APs are associated with essential enzymatic 
activity such as conservation of metal binding sites, amino acids required for activity, and 
predicted fold structure. AP also have been associated with endogenous microbes’ interaction 
and signaling to other cells.34 L1 and L2 are positive for leucine arylamidase, while valine 
arylamidase, is present in L2. Leucine arylamidase and valine arylamidase belong to a group of 
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exo-amino peptidases, which have been associated with decomposition of nitrogen polymers.35 
N-Acetyl-/β-glucosaminidase (NAG) is found to be positive in L1 and L2. NAG is a hydrolytic 
lysosomal enzyme that breaks down glycosides and amino sugars that form structural 
components for the degradation and disposal of various parts of the cell, including the cell 
membrane. Results from this assay will be used to help identify possible proteins that potentially 
have inhibitory activity against M. smegmatis in further tests. 
 
Table 3.6.1. Enzymatic activity detected by the API-ZYM assay. Strains were grown in YMB 
liquid medium at 30 °C for 14 days. Protein extract (65 μl) was dispensed into each well of a 20 
API-ZYM strip micro-tube and the reaction was incubated at 30 °C for 5 hours. After the 
incubation period, a drop of ZYM A and ZYM B reagent was added. The color reaction was read 










Enzymes L. albida L. albiodocapillata 
negative control   
alkaline phosphatase   
esterase   
esterase lipase   
lipase   
leucine arylamidase   
valine arylamidase   
cystine arylamidase   
trypsin   
α-chymotrypsin   
acid phosphatase   
naphthol phosphohydrolase   
α-galactosidase   
β-galactosidase   
β-glucuronidase   
α-glucosidase   
β-glucosidase   
N-acetyl-β-glucosaminidase   
α-mannosidase   
α-fucosidase   
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3.7 Extraction from media and Solubility Tests  
 
After two weeks, agar extraction of L1 and L2 cultures were initially conducted using 
ethyl acetate. Extraction solvent was then changed to chloroform:MeOH and finally to acetone. 
All agar-solvent mixtures were then subjected to rotary evaporation to obtain the concentrated 
agar and Lentzea extracts. These extracts were then used for future analysis.  
Dissolving the evaporated extract concentrates with HPLC-grade methanol for LC run 
preparation was one of the significant problems in isolating the active compound in the extract 
samples. When ethyl acetate extracts were dissolved in methanol, the solid dissolved most of the 
time. However, white precipitates tended to form in the solution (Figure 3.7.3). These 
precipitates likely result from decomposition of proteins or peptides when methanol is 
introduced. Methanol is a very polar solvent and therefore will create a non-ideal environment 
for hydrophobic parts of the proteins or peptides in the extracted sample. When 
chloroform:MeOH extracts were reconstituted in MeOH, white precipitates formed in the 
solution and the evaporated concentrates did not dissolve and remained at the bottom of the vial. 
These undissolved extracts were stored and another batch of Lentzea agar cultures were extracted 
with another solvent, acetone. For acetone extracts, solubility tests were conducted using 
acetone, acetonitrile, ethanol, and MeOH (Figure 3.7.4). All acetone extracts dissolved well 
using MeOH. Since acetone extracts were dissolved using HPLC-grade MeOH, MeOH was then 
used for further LC and QTOF analysis. 
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Figure 3.7.1. Extraction of Control agar; L1 agar, and L2 agar extracts using ethyl acetate. 2-
weeks old control agar, L1 on agar, and L2 on agar that were incubated at 30°C  
 
 
    
  
Figure 3.7.2. Extracts of Lentzea strains in ethyl acetate and concentrated. Extracts used for 
LC/MS analysis, see Figure 12. 
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Figure 3.7.3. Concentrated crude Lentzea extracts dissolved in MeOH. Notice white precipitate 




Figure 3.7.4. Solubility test for L2-acetone extract. A small amount of evaporated L2-acetone 
extract was dissolved in MeOH, 95% EtOH, Acetone, and ACN. Note complete solubility of 
solid extract on MeOH. 
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3.8 Well-Diffusion Method 
After 3-7 days of growth, the growth of M. smegmatis surrounding the treated wells were 
observed for presence of activity. Ethyl acetate extracts of agar control, L1, and L2 were tested 
against M. smegmatis. L1 and L2 were found to inhibit the growth of M. smegmatis. However, 
inhibition of M. smegmatis growth was not consistent after the procedure was replicated multiple 
times for new batches. Well-diffusion tests were also conducted with the collected fractions of 
crude ethyl acetate extracts that were subjected to reverse-phase column chromatography (Figure 
3.7.2).  
Since the results with ethyl acetate extracts were not consistent, another solvent mixture, 
chloroform:MeOH, was used for extraction with the assumption that chloroform:MeOH will be 
more powerful for pulling out active secondary metabolites produced by Lentzea strains. 
However, precipitate formed when the evaporated chloroform:MeOH agar extracts were 
resuspended using MeOH for further analysis. 
Another extraction solvent, acetone, was used to extract another batch of samples. 
Concentrated acetone extracts were used for another well-diffusion assay. It was observed that 
there is no growth of M. smegmatis around L1 and L2 Acetone extracts (Figure 3.8.3). This 
suggests that using acetone as an extraction solvent is effective for getting the active metabolites 
from the agar media inoculated with L1 and L2. However, contamination of unidentified 
microbes surrounding the treated wells were observed (Figure 3.8.3). To prevent contamination, 
previous and further concentrated extracts were then filtered using 0.2 µm PTFE syringe filters 
before storage and/or further tests and analysis.  
Crude extracts were also subjected to reverse-phase column chromatography packed with 
activated C-18 resin. Collected fractions were used for another well-diffusion assay procedure 
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similarly conducted to previous tests for activity. Inhibition of M. smegmatis growth was found 
at wells surrounding 80% ACN for L1 extracts, while for L2 extract, the activity was observed at 
80% and 100% ACN (Figure 3.8.4). 
 
 
Figure 3.8.1 Crude Lentzea ethyl acetate extracts using micro-column chromatography. Note 
inhibition at L1DY and L2. 
 
 
   
Figure 3.8.2. Crude and fractionated lentzea ethyl acetate extracts using micro-column 
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Figure 3.8.4. Bioassay of filtered crude Lentzea-acetone extracts against M. smegmatis. 
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3.9 Chromatography Analysis 
3.9.1 Thin Layer Chromatography (TLC) Analysis 
The plate was observed and photographed under UV light at 254 and 365 nm. L1 and L2 
extracts and fractions were not well separated for all TLC analysis. This makes the analysis 
difficult to determine the polarity of the compounds present in each sample. 
 
Figure 3.9.1.1. TLC of L1 and L2 fractions using hexane and methanol as mobile phase. 60%, 
80%, and 100% ACN L1 fractions; 40%, 80%, and 100% ACN L2 fractions 
 
     
Figure 3.8.1.2. TLC of Control agar, L1, and L2 Acetone extract observed under short wave and 
long wave UV light.  
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3.9.2 Reverse-phase Column Chromatography  
Micro-column chromatography was also conducted to further separate and identify 
the active compound(s) responsible for M. smegmatis inhibition present in crude Lentzea 
extracts. Each of the collected fractions was then subjected to bioassays against M. smegmatis 
using the well-diffusion method to identify the active fraction (Figure 3.8.2 and Figure 3.8.3).  
Well-diffusion assays against M. smegmatis using collected fractions of ethyl acetate extracts 
indicate that the active metabolite(s) elute at 80% ACN for L1 and at 80% and 100% ACN for 
L2. However, results were not consistent when trials were repeated.  
As mentioned earlier, this suggests that the active metabolite(s) was either not pulled by 
ethyl acetate solvent or that the ethyl acetate may be causing the active metabolite to decompose.   
Another batch of concentrated acetone extracts were also fractionated using column 
chromatography. Similarly, to the ethyl acetate extract fractions, eluted acetone extract fractions 
were also tested against M. smegmatis using the well-diffusion method. It appears that the active 
compounds produced by L1 eluted at 100% ACN, while those of L2 eluted at 80% ACN and 
100% ACN. This treatment was replicated, and the results were found to be consistent. 
Therefore, results from LC/MS, LC (only UV-Vis), and QTOF analysis were focused on 
significant peaks eluted in the gradient from 70% to 100% ACN.  
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3.9.3 Liquid Chromatography/Mass Spectroscopy (LC/MS) 
 
 
With the help of Patricia Granados, LC/MS analysis was performed for these extracts in 
the CEAR Lab at Saint Mary’s University. LC-MS procedure was based on Kaitlyn Blatt-
Janmaat’s previous work. 
 
Analysis for Ethyl-Acetate Extracts 
LC elution for Ethyl-Acetate 
Extracts was started at ACN:H2O at 20% 
for 24 minutes; 80% for the next 3 
minutes; and finally 100% at 28 minutes. 
It appears that most of the compounds in 
the extracts elute early around 20% ACN 
gradient for the first 5 minutes (Figure 
3.9.3.1 and Figure 3.9.3.2). This indicates 
that the eluted compounds in this gradient 
are polar and are UV-Vis active. 
The compounds detected 
corresponding to each peak are yet to be 
identified. However, compounds eluted from this 
gradient are believed to not have activity against M. 
smegmatis if the column used in LC would behave 
similarly to manual column chromatography done 
before (refer to Results in sections 3.9.2 and 3.8).  
Figure 3.9.3.1. UV-Vis Spectra of collected crude 
extracts of Agar control, L. albida (normal and darker 
media), and L. albiodocapillata. LC elution was 
started at ACN:H2O at 20% for 24 min; 80% for the 







Figure 3.9.3.2. UV-Vis Spectra of 
collected crude extracts of Agar control, 
L. albida (normal and darker media), and 
L. albiodocapillata.  
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Interestingly, the LC/MS run for the MeOH control sample showed presence of 
unidentified compounds eluting from the column for two minutes (Figure 3.9.3.1). This sample 
is used as a blank sample run and is expected to yield very few signals because there is no 
analyte in the sample. The first two minutes of the run were then ignored for analysis purposes 
and it was focused on the peaks present in the TIC and UV-Vis chromatogram in L1 and/or L2 
only. For the L1 sample, the UV-Vis Chromatogram shows a weak peak labelled 1 (Figure 
3.9.3.3). This peak is assumed to correspond with the peak seen in the TIC, which has high noise 
in the mass spectra eluted around 4 minutes. 
  
  
Figure 3.9.3.3. LC/MS Analysis for L1 Ethyl-Acetate Extracts. Note peak labelled 1 on the TIC 
is weakly UV-Vis active and have high noise in mass spectra eluted around 4 minutes. LC 
elution was started at ACN:H2O at 20% for 24 minutes; 80% for the next 3 minutes; and finally 








58 | P a g e  
 
For L2 sample, TIC peak labelled 1 was not UV-Vis active (Figure 3.9.3.3). Interestingly, 
this peak shows a single mass of 2179.6 when the mass spectrum was analyzed at the same time 
(Figure 3.9.3.4). While TIC peak labelled 2 has weak UV-Vis signal and shows a series of 
multiple peaks on Mass Spectra with 282.1 as having the highest intensity corresponding to this 
TIC peak (Figure 3.9.3.4). However, compounds eluted at a gradient of 20% ACN at this time 
(around 4 minutes). The chloroform:methanol extract were not analyzed using LC/MS due to 





Figure 3.9.3.4. LC/MS Analysis for L2 Ethyl-Acetate Extracts. Note peaks labelled 1 and 2 on 
the TIC have very weak UV-Vis signal eluted around 4 minutes. TIC peak labelled 1 show a 
single mass of 2179.6 while peak labelled 2 show a series of multiple peaks with 282.1 as being 
the highest mass on Mass Spectra corresponding to these two TIC peaks. LC elution was started 
at ACN:H2O at 20% for 24 minutes; 80% for the next 3 minutes; and finally 100% at 28 minutes.  
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Analysis for Acetone Extracts 
 
LC runs for L1 and L2 Acetone extracts were conducted for the following wavelengths: 
195, 203, 205, 212, and 274 nm. UV-Vis LC chromatogram of agar control, L1 and L2 were 
compared to one another. UV-Vis active compounds that are only present on L1 and L2 acetone 
extracts were noted (refer to Table 3.9.3.1.).  
 
Table 3.9.3.1. LC-UV-Vis Analysis of L1 and L2. LC run for L1 and L2 Acetone extracts were 
conducted for the following wavelength 195, 203, 205, 212, and 274 nm. UV-Vis active 
compounds that are only present on L1 and L2 Acetone extracts.  




Wavelength (nm) Rt (min) (%) ACN Gradient  Rt (min) (%) ACN Gradient  
195 4.758 30-50 4.842 30-50    
18.989 70 
203 4.758 30-50 4.844 30-50    
18.988 70 
205 4.761 30-50 4.847 30-50    
18.987 70 
212 3.73 30-50 
  











3.9.4 UV-Vis Spectroscopy Analysis 
 
UV-Vis analysis shows that UV-Vis active molecules present in the tested fractions 
absorb at low levels around 200 nm (Table 3.10.1). This data agrees with the initial findings in 
the detected UV-Vis LC chromatogram when the samples were run using Liquid 
Chromatography (refer to 3.9.3 for Acetone Extracts). Comparably, the 20% ACN fraction for 
both L1 and L2 contains many UV-Vis active compounds. This supports the results from the LC 
analysis of Acetone extracts, where multiple UV-Vis active compounds were also found in the 
20% ACN fractions.  
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Table 3.9.1 Maximum wavelength of collected L1 and L2 ethyl acetate extract fractions. Active 












Sample (% ACN) Abs Maximum wavelength (nm) 
20 L2 1 228  
1 219  
1 216  
1 214  
1 207  
1 205 
20 L2 replicate 2 1 237  
1 232  
1 228 
40 L2 1 206 
60 L2 0.854 212 
80 L2 0.42 203 
100 L2 0.34 206 
20 L1 1 274  
1 272  
1 269  
1 267  
1 263  
1 259  
1 256  
1 254  
1 252  
1 248  
1 241  
1 236  
1 232  
1 228  
1 215 
40 L1 1 212 
60 L1 0.904 211 
80 L1 1 203 
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3.9.5 HRMS(QTOF) analysis 
 
QTOF analysis was conducted for a MeOH Control, Agar Control acetone extract, L1 
acetone extract and L2 acetone extract. The TIC of MeOH sample was expected to be the blank 
and was used as a control for comparing with Agar Control, L1, and L2 samples. However, The 
column elutes unidentified compounds when the MeOH Control sample was run in the QTOF 
(Figure 3.9.5.1). A large peak was observed at approximately 14 minutes where the gradient was 
likely around 60% ACN:H2O. Elution of more ‘junk or unidentified contaminants’ appeared to 










Figure 3.9.5.1. TIC Scan of (A) MeOH Control Sample and 
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TIC of MeOH Control sample was used to compare TIC of other samples and determine 
peaks and mass spectra that are only present in L1 and L2 samples. Additionally, mass spectra of 
the Agar Control were processed by taking the original mass spectra corresponding to the Agar 
Control sample subtracted by the mass spectra taken from MeOH Control sample at the same 
retention time. TIC data corresponding to agar control, L1, and L2 samples were compared. 
Peak(s) observed to be present in the L1 and/or L2 samples but are not in the agar control sample 
were recorded.  
Acquiring a good separation of metabolites unique to L1 and/or L2 is important.  
This will enable us to isolate the active compound in Lentzea samples and compare the mass 
spectra observed against the mass spectra of known metabolites reported in the literature. 
For example, we can use the peak present in the mass spectra of Lentzea samples that has a mass 
ratio of 485.3961 m/z at time 9.96 minutes (Table 3.9.5.1 and Appendix). Looking at the 
MassBank of North America, a compound called Cypridinid luciferin enol sulfate was found to 
have a similar mass of 485.1845. Additionally, a peak present at L2 sample with a mass-to-
charge ratio of 749.3753 m/z was found to be similar with 2,3-dihydromicrocolin A which have 
a mass of 749.49. Cypridinid luciferin enol sulfate is known as a luminous substrate while 2,3-
dihydromicrocolin A has a potent cytotoxic and immunosuppressive properties. Using this 
approach will give us an idea of the identity and possible function of the active metabolites 
produced by Lentzea samples. To clarify, comparisons made here will be used as a starting point 
to examine any common trends of compounds with similar mass. 
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A hypothesis of why high noise on all samples were observed is due to the contaminated 
C-18 column in the HPLC instrument. TIC data for all samples were found to have a high 
amount of unidentified contaminants to elute at higher ACN concentration in the mobile phase.  
After an intensive cleaning of the C-18 
column, a significant decrease of noise in 
the TIC scan of the MeOH sample run from 
March 2nd was observed compared to the 
initial MeOH run, Figure 3.9.5.2 and Table 
3.9.5.1. Overlapping the initial MeOH, 
March 2nd MeOH, and March 2nd ACN run 
also shows a significant decrease of peaks 
eluted from March 2nd MeOH, and March 2nd 
ACN. Low baseline like this is expected since MeOH is only used for dissolving the 
concentrated agar samples while ACN is used as an organic solvent for the mobile phase in the 
HPLC/HRMS. The decrease of baseline observed suggests that the column used for separation 
was contaminated by an unidentified mixture of compounds. The unidentified compounds 
seemed to elute out of the column after a series of cleaning runs.  
Knowing that the column was contaminated, it will be good idea to routinely conduct an 
extensive cleaning of the column and adding a pre-column or guard column for separation to 
minimize this event from occurring in the future. Installation of a guard column will also affect 




Figure 3.9.5.2. Overlapping TIC scans of initial MeOH 
(red), March 2nd MeOH (pink), and March 2nd ACN 
samples. Note the significant difference between initial 
MeOH and to other samples.  
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Figure 3.9.5.3. Compounds reported in the literature with similar M/Z ratio of unidentified 
metabolites produced by L1 and L2. (1) cypridinid luciferin enol sulfate, (2) 2,3-
dihydromicrocolin A, (3) Podophyllin Acetate, (4) CarmaphycinA_enone, (5) Dihydrogedunic 
Acid, Methyl Ester, (6) 8-Hydroxycarapinic Acid, (7) Maraviroc, (8) DAMGO, (9) 
Carminomycin I, (10) Anandamide O phosphorylcholine, (11) trans-Zeatin riboside-O-glucoside 
 
Table 3.9.5.2. Mass Spectra of HPLC/HRMS run for initial MeOH, March 2nd MeOH, and 
March 2nd ACN run. Note the difference of prominent peaks observed from initial MeOH run 
and samples run on March 2nd. See Appendix for more information. 
Sample Rt. 9.3 min (m/z) Rt. 11.23 min (m/z) Rt. 14.0 min (m/z) 
MeOH  289.1049 337.1078 284.3794 
MeOH Mar 2nd  224.1275 224.1274 224.1280 









1 2 3 
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Chapter 4: Conclusion 
 
In summary, it was found that, like L. kentuckyensis, other closely related microbes such 
as L. albida and L. albiodocapillata can produce compounds that inhibit the growth of M. 
smegmatis. The active compound produced by these two Lentzea strains can be extracted by 
using acetone solvent from the agar media. The active compound can be isolated further by 
reverse-phase column chromatography using increasing concentrations of Acetonitrile and water 
as mobile phase. Specifically, the active metabolite(s) for L1 was eluted at 80% ACN. On the 
other hand, the active compound(s) for L2 elutes at 80% ACN and 100% ACN. Further analysis 
to isolate and identify the active compound has been attempted by using automated separation 
apparatus such as HPLC/HRMS(Q-TOF). Further development of an automated separation 
process still needs to be optimized to yield a consistent result and characterize the structure of the 
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Chapter 5: Future Work  
Future direction of this project is to continue running reversed-phase 
HPLC/HRMS(QTOF) to identify the active metabolites produced by Lentzea strains.   
Adjustments with the HPLC/HRMS(QTOF) instrument are required to improve data. For 
instance, a pre-guard column will be installed to prevent contamination of C-18 column 
responsible for separation of compounds in each sample. The column will have to be thoroughly 
cleaned before every run is conducted. Then, starting HPLC/HRMS run using MeOH control, 
agar control, L1, and L2 samples would be a good idea. This would enable us to determine 
whether a better separation of compounds is achieved in this run compared to the previous run. 
Better data difference observed, i.e. significant decrease of noise on the TIC data and low TIC 
baseline of MeOH control, indicates that this procedure is better. Active metabolites then can be 
characterized by in-depth analysis of HRMS data of the Lentzea samples. The processed mass 
spectra of the Lentzea samples can then be compared to compounds reported in the literature 
using the available mass spectral records like MassBank North America (MoNA). 
Furthermore, separation of compounds can be improved by using the 2D-LC and have an 
automated way of collecting the fractions. The elution gradient could also be manipulated for 
better separation of compounds. Each collected fraction will then be retested against M. 
smegmatis to further locate the compound with the inhibitory activity.  
HRMS method development could also be improved for future studies. For instance, both 
positive and negative ESI mode can be used for better MS coverage.  
Structure elucidation and characterization will then be conducted using methods like IR, 
HRMS(QTOF), HRNMR and elemental analysis.  
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Once the active compound is isolated, future studies may focus on the investigation of the 
precise mechanism of action of the active compound and will be tested against M. 
tuberculosis by a collaborator from Kerr research group. Any novel compounds we characterize 
will provide a better understanding of how Lentzea strains interact with and defend themselves 
against competing microbes, such as mycobacteria.  
Additional studies of genomic sequence comparison between L1 and L2 against 
L. kentukyensis can also be done to understand the mechanism of observed activity. Conducting 
an induced stress response study on the Lentzea strains could also be done to check more 
interesting activity (i.e. stronger inhibition in the presence of a stressor). It will also be 
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Appendix 
A. UV-Vis Spectrometer Data 
 
Figure A.1. UV-Vis Chromatogram of 20% ACN L2 Acetone Extract. Concentrated YMA media 
extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 20% ACN 
and found to have no effect on the growth of M. smegmatis.  
 
Figure A.2. UV-Vis Chromatogram of 40% ACN L2 Acetone Extract. Concentrated YMA media 
extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 40% ACN 
and found to have no effect on the growth of M. smegmatis.  
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Figure A.3. UV-Vis Chromatogram of 60% ACN L2 Acetone Extract. Concentrated YMA media 
extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 60% ACN 
and found to have no effect on the growth of M. smegmatis.  
 
Figure A.4. UV-Vis Chromatogram of 80% ACN L2 Acetone Extract. Concentrated YMA media 
extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 80% ACN 
and found to inhibit the growth of M. smegmatis.  
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Figure A.5. UV-Vis Chromatogram of 100% ACN L2 Acetone Extract. Concentrated YMA media 
extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 100% 
ACN and found to inhibit the growth of M. smegmatis.  
 
Figure A.6. UV-Vis Chromatogram of 20% ACN L1 Acetone Extract. Concentrated YMA media 
extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 20% ACN 
and found to have no effect on the growth of M. smegmatis. 
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Figure A.7. UV-Vis Chromatogram of 40% ACN L1 Acetone Extract. Concentrated YMA media 
extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 40% ACN 
and found to have no effect on the growth of M. smegmatis. 
 
Figure A.8. UV-Vis Chromatogram of 60% ACN L1 Acetone Extract. Concentrated YMA media 
extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 60% ACN 
and found to have no effect on the growth of M. smegmatis. 
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Figure A.9. UV-Vis Chromatogram of 80% ACN L1 Acetone Extract. Concentrated YMA media 
extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 80% ACN 
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Appendix B. TIC scans of MeOH, agar, L1, and L2 samples.  
 
Figure B.1. TIC Scan of MeOH Control Sample. HPLC-Grade MeOH sample was subjected 
to QTOF analysis run in positive mode. The ACN (0.1% Formic acid):H2O (0.1% Formic acid) 
mobile phase gradient of elution started at 10% ACN then at 3 minutes to 30% ACN; then at 5 
minutes to 50% ACN; then at 10 minutes 60% ACN; then at 15 minutes to 70% ACN; then 20 
minutes to 80% ACN; then at 25 minutes to 90% ACN; then at 30 minutes to 100% ACN; And 
finally at 35 minutes to 100% ACN.  
 
Figure B.2. Overlapped TIC of all samples. HPLC-Grade MeOH sample was subjected to QTOF 
analysis run in positive mode. The ACN (0.1% Formic acid):H2O (0.1% Formic acid) mobile 
phase gradient of elution started at 10% ACN then at 3 minutes to 30% ACN; then at 5 minutes 
to 50% ACN; then at 10 minutes 60% ACN; then at 15 minutes to 70% ACN; then 20 minutes to 
80% ACN; then at 25 minutes to 90% ACN; then at 30 minutes to 100% ACN; And finally at 35 
minutes to 100% ACN.  




Figure B.3. Mass Spectra of Agar Control, L1, L2, and MeOH Control samples. Note 
highlighted peaks in the mass spectra that are only present in L1 and/or L2 samples. Estimated 
gradient elution is around 50-60% ACN.  
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Figure B.4. TIC of Agar Control, L1, L2, and MeOH Control samples run in QTOF 
analysis. Note each line on each TIC which corresponds to the mass spectra estimated to be 
eluted around 50-60% ACN at 10 minutes and 8 seconds.   










Figure B.5. Mass Spectra of Agar Control, L1, L2, and MeOH Control samples. Note 
highlighted peak in the mass spectra that are only present in L1 and L2 sample. Estimated 
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Figure B.6. TIC of Agar Control, L1, L2, and MeOH Control samples run in QTOF 
analysis. Note each line on each TIC which corresponds to the mass spectra estimated to be 
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Figure B.7. Mass Spectra of Agar Control, L1, L2, and MeOH Control samples. Note 
highlighted peak in the mass spectra that are only present in L1 sample. Estimated gradient 
elution is around 50-60% ACN at 10 minutes and 9 seconds.  
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Figure B.8. TIC of Agar Control, L1, L2, and MeOH Control samples run in QTOF 
analysis. Note each line on each TIC which corresponds to the mass spectra estimated to be 
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Figure B.9. Mass Spectra of Agar Control, L1, L2, and MeOH Control samples. Note 
highlighted peak in the mass spectra that are only present in the L1 sample. Estimated gradient 
elution is around 60% ACN at 12 minutes and 8 seconds.  
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Figure B.10. Overlapping TIC scans of initial MeOH (red), March 2nd MeOH (pink), and March 
2nd ACN samples. Note the significant difference between initial MeOH and to other samples.  
 
 
Figure B.11. TIC scans of initial MeOH (red), March 2nd MeOH (pink), and March 2nd ACN 
samples. Note the significant difference between initial MeOH and to other samples.  
 
87 | P a g e  
 
 
Figure B.12. Overlapping TIC scans of initial MeOH (red), March 2nd MeOH (pink), and March 
2nd ACN samples. Note the significant difference between initial MeOH and to other samples. 
NOTE difference of peaks. 224.1287 or 224.1275 seems to be present in clean MeOH and ACN controls. 
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Appendix C. IR Spectra of agar, L1, and L2 samples. 
 
Figure C.1. IR Spectra of 20% ACN Agar Control Fraction. Concentrated YMA media extracted using 
acetone was subjected to reverse-phase chromatography. Extract was eluted at 20% ACN and found to 
have no affect on the growth of M. smegmatis.  
 
Figure C.2. IR Spectra of 20% ACN L1-Agar Fraction. Concentrated YMA media inoculated with L1 for 
two weeks extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 
20% ACN and found to have no effect on the growth of M. smegmatis.  
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Figure C.3. IR Spectra of 40% ACN L1-Agar Fraction. Concentrated YMA media inoculated with L1 for 
two weeks extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 
40% ACN and found to have no effect on the growth of M. smegmatis.  
 
Figure C.4. IR Spectra of 60% ACN L1-Agar Fraction. Concentrated YMA media inoculated with L1 for 
two weeks extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 
60% ACN and found to have no effect on the growth of M. smegmatis.  
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Figure C.5. IR Spectra of 80% ACN L1-Agar Fraction. Concentrated YMA media inoculated with L1 for 
two weeks extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 
80% ACN and found to inhibit the growth of M. smegmatis.  
 
Figure C.6. IR Spectra of 100% ACN L1-Agar Fraction. Concentrated YMA media inoculated with L1 
for two weeks extracted using acetone was subjected to reverse-phase chromatography. Extract was 
eluted at 100% ACN and found to have no effect on the growth of M. smegmatis.  
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Figure C.7. IR Spectra of 20% ACN L2-Agar Fraction. Concentrated YMA media inoculated with L2 for 
two weeks extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 
20% ACN and found to have no effect on the growth of M. smegmatis.  
 
Figure C.8. IR Spectra of 40% ACN L2-Agar Fraction. Concentrated YMA media inoculated with L2 for 
two weeks extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 
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Figure C.9. IR Spectra of 60% ACN L2-Agar Fraction. Concentrated YMA media inoculated with L2 for 
two weeks extracted using acetone was subjected to reverse-phase chromatography. Extract was eluted at 
60% ACN and found to have no effect on the growth of M. smegmatis.  
 
Figure C.10. IR Spectra of 80% ACN L2-Agar Fraction. Concentrated YMA media inoculated with L2 
for two weeks extracted using acetone was subjected to reverse-phase chromatography. Extract was 
eluted at 80% ACN and found to inhibit the growth of M. smegmatis.  
93 | P a g e  
 
 
Figure C.11. IR Spectra of 100% ACN L2-Agar Fraction. Concentrated YMA media inoculated with L2 
for two weeks extracted using acetone was subjected to reverse-phase chromatography. Extract was 
eluted at 100% ACN and found to inhibit the growth of M. smegmatis.  
